1. Assessing a Patient’s Individual Risk of Biopsy-detectable Prostate Cancer: Be Aware of Case Mix Heterogeneity and A Priori Likelihood 
Jan F.M. Verbeek, Daan Nieboer, Ewout W. Steyerberg, Monique J. Roobol 
European Urology Oncology 
DOI: /j.euo
Copyright © Terms and Conditions

2. Fig. 1
Calibration plot: observed proportion versus predicted probability according to the ERSPC-MRI risk calculator (RC) with and without intercept adjustment in a cohort with lower prevalence of clinically significant prostate cancer than in the development cohort. Shading depicts the 95% confidence intervals. The ERSPC-MRI RC predicts clinically significant prostate cancer on systematic and targeted biopsies on the basis of information on prostate-specific antigen, digital rectal examination, prostate volume, age, previous negative biopsy, and Prostate Imaging-Reporting and Data System score.
European Urology Oncology DOI: ( /j.euo )
Copyright © Terms and Conditions

3. Fig. 2
Decision curve analysis. Net benefit of the ERSPC-MRI risk calculator (RC) compared to biopsy-all and biopsy-none strategies in a cohort with lower prevalence of clinically significant prostate cancer than for the development cohort both before (red dashed line) and after (blue solid line) adjustment. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
European Urology Oncology DOI: ( /j.euo )
Copyright © Terms and Conditions